Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Cancer|February 27, 2010
A new era in anticancer peptide vaccinesSonia A Perez, Eric von Hofe, Nikoletta L Kallinteris, et al.International Journal of Cancer|July 20, 2007
Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chainIoannis F Voutsas, Angelos D Gritzapis, Louisa G Mahaira, et al.Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2005
Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious diseaseNikoletta L Kallinteris, Douglas Powell, Catherine E Blackwell, et al.Current Opinion in Molecular Therapeutics|June 16, 2004
Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II moleculesMinzhen Xu, Xueqing Lu, Nikoletta L Kallinteris, et al.Human Gene Therapy|March 12, 2005
Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii proteinYu Wang, Minzhen Xu, Mingxin Che, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2008
Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramersLaurence Van Overtvelt, Erik Wambre, Bernard Maillère, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2010
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancerSonia A Perez, Nikoletta L Kallinteris, Stratos Bisias, et al.Cancer Immunology, Immunotherapy : CII|September 9, 2006
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumorsNectaria N Sotiriadou, Nikoletta L Kallinteris, Angelos D Gritzapis, et al.Cancer Immunology Research|August 3, 2021
Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor ResponsesYanping Yang, Jaclyn E McCloskey, Huan Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJarrod P Holmes, Linda C Benavides, Jeremy D Gates, et al.Pageof 3